Subject no. | Sex | Age (y) | Cohort | Injected dose (MBq) | β-amyloid status (visual) | β-amyloid global SUVR* | β-amyloid centiloid score† | ADAS-Cog score | Clinical dementia rating score | MMSE Score |
1 | Female | 65 | HC | 341.5 | Negative | 1.00 | −2 | 5 | 0 | 29 |
2 | Female | 75 | HC | 339.7 | Negative | 0.91 | −16 | 7 | 0 | 30 |
3 | Male | 61 | HC | 333.4 | Negative | 1.00 | −1 | 3 | 0 | 30 |
4 | Male | 51 | HC | 347.8 | Negative | 1.02 | 2 | 6 | 0 | 29 |
5 | Female | 53 | HC | 353.4 | Negative | 1.03 | 3 | 5 | 0 | 29 |
6 | Male | 56 | HC | 347.1 | Negative | 0.98 | −5 | 2 | 0 | 26 |
7 | Male | 50 | HC | 332.6 | Negative | 1.04 | 5 | 6 | 0 | 28 |
8 | Male | 66 | HC | 353.4 | Negative | 1.01 | 0 | 9 | 0 | 30 |
9 | Male | 60 | HC | 299.0 | Negative | 1.03 | 4 | 3 | 0 | 30 |
10 | Female | 55 | HC | 262.7 | Negative | 0.94 | −10 | 3 | 0 | 29 |
11 | Male | 58 | AD | 346.3 | Positive | 1.99 | 150 | 19 | 0.5 | 20 |
12 | Female | 63 | AD | 333.4 | Positive | 1.67 | 101 | 16 | 0.5 | 28 |
13 | Male | 71 | AD | 335.2 | Positive | 1.66 | 100 | 22 | 0.5 | 20 |
14 | Female | 63 | AD | 339.3 | Positive | 1.83 | 126 | 53 | 2 | 8 |
15 | Male | 70 | AD | 352.2 | Positive | 1.66 | 100 | 32 | 0.5 | 22 |
16 | Male | 80 | AD | 351.1 | Positive | 1.53 | 79 | 14 | 0.5 | 17 |
17 | Male | 72 | AD | 343.7 | Positive | 1.73 | 111 | 41 | 2 | 8 |
18 | Male | 77 | AD | 336.7 | Positive | 1.62‡ | 102 | 16 | 0.5 | 26 |
19 | Male | 76 | AD | 347.4 | Positive | 1.47 | 71 | 13 | 1 | 27 |
20 | Female | 56 | AD | 359.6 | Positive | 1.71 | 108 | 22 | 0.5 | 23 |
21 | Male | 83 | AD | 349.3 | Positive | 1.47‡ | 76 | 16 | 0.5 | 23 |
22 | Female | 53 | AD | 348.2 | Positive | 1.57 | 85 | 25 | 0.5 | 23 |